OTCMKTS:DSNKY Daiichi Sankyo (DSNKY) Stock Price, News & Analysis $22.88 -0.08 (-0.35%) As of 06/27/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort InterestBuy This Stock About Daiichi Sankyo Stock (OTCMKTS:DSNKY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Daiichi Sankyo alerts:Sign Up Key Stats Today's Range$22.10▼$23.1050-Day Range$22.66▼$27.2252-Week Range$20.92▼$42.48Volume208,671 shsAverage Volume193,539 shsMarket Capitalization$43.34 billionP/E Ratio22.21Dividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company OverviewDaiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.Read More… Receive DSNKY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Daiichi Sankyo and its competitors with MarketBeat's FREE daily newsletter. Email Address DSNKY Stock News HeadlinesDaiichi Sankyo Co Ltd ADR News (DSNKY) - Investing.comJune 26 at 12:48 AM | investing.comFDA Approves AstraZeneca And Daiichi Sankyo's Datroway For Type Of Lung CancerJune 24, 2025 | benzinga.comGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powerful is happening behind the scenes… Some investors are using a little-known ETF to collect up to $1,152/month from gold's surge. No trading gold futures. No mining stocks. No vaults. Just a simple fund delivering monthly payouts — like clockwork.June 29 at 2:00 AM | Investors Alley (Ad)Daiichi Sankyo (OTCMKTS:DSNKY) Shares Down 0.1% - Should You Sell?June 20, 2025 | americanbankingnews.comDaiichi Sankyo, AstraZeneca Announce Promising DATROWAY Combination Data in NSCLCJune 2, 2025 | msn.comMerck, Daiichi Sankyo pull marketing application for lung cancer therapyMay 29, 2025 | msn.comDaiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-Changing Data at ASCOMay 22, 2025 | businesswire.comWayfinder Biosciences and Daiichi Sankyo collaborate to develop novel RNA-targeting therapies for neurodegenerative diseaseApril 15, 2025 | tmcnet.comSee More Headlines DSNKY Stock Analysis - Frequently Asked Questions How have DSNKY shares performed this year? Daiichi Sankyo's stock was trading at $27.29 at the beginning of 2025. Since then, DSNKY stock has decreased by 16.2% and is now trading at $22.88. View the best growth stocks for 2025 here. How were Daiichi Sankyo's earnings last quarter? Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY) announced its quarterly earnings results on Friday, April, 25th. The company reported $0.30 earnings per share for the quarter. The company earned $3.40 billion during the quarter. Daiichi Sankyo had a trailing twelve-month return on equity of 17.92% and a net margin of 15.65%. How do I buy shares of Daiichi Sankyo? Shares of DSNKY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings4/25/2025Today6/29/2025Next Earnings (Estimated)7/29/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:DSNKY Previous SymbolOTCMKTS:DSNKY CIKN/A Webwww.daiichisankyo.com Phone(136) 225-1111FaxN/AEmployees17,435Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$1.03 Trailing P/E Ratio22.21 Forward P/E Ratio31.34 P/E Growth1.17Net Income$1.95 billion Net Margins15.65% Pretax Margin18.85% Return on Equity17.92% Return on Assets8.61% Debt Debt-to-Equity Ratio0.06 Current Ratio2.53 Quick Ratio1.85 Sales & Book Value Annual Sales$12.39 billion Price / Sales3.50 Cash Flow$1.26 per share Price / Cash Flow18.23 Book Value$5.61 per share Price / Book4.08Miscellaneous Outstanding Shares1,894,350,000Free FloatN/AMarket Cap$43.34 billion OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (OTCMKTS:DSNKY) was last updated on 6/29/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daiichi Sankyo Co., Ltd. - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Daiichi Sankyo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.